Q4 results today: What's in store for Tata Motors, DLF, Vedanta and Cipla?

Tata Motors, DLF, Vedanta and Cipla will announce their fourth-quarter results on Friday. Here is a preview of what to expect from these companies:

Tata Motors
Tata Motors is expected to come up with healthy numbers for the quarter ended March, led by EBITDA margin expansion across divisions and also strong India and JLR business.

The company is expected to report a net profit anywhere between Rs 3,100-3,204 crore, according to an average estimate of five brokerages. The Mumbai-based auto major had posted a loss of Rs 1,032 crore in the year-ago quarter.

Revenue from operations, meanwhile, is expected to rise up to 34% to Rs 1.06 lakh crore in the fourth quarter.

DLF
DLF is expected to post a marginal increase in its net profit at Rs 477 crore.

The company reported strong pre-sales numbers, with a contribution of Rs 800 crore from Arbour and the launch of the last tower in mid-town.

Kotak Institutional estimates revenue recognition of Rs 1,260 crore in the fourth quarter, owing to moderated delivery.

Net sales are expected to plunge 18% year-on-year (YoY) to Rs 1,268 crore during the March quarter, according to an average estimate of two brokerages.

Vedanta
Vedanta's net profit is likely to decline by 48% year-on-year, according to an average estimate of two brokerages. The profit figure is likely to be anywhere between Rs 2,168 crore - Rs 2,618 crore.

Investors will watch out for management updates on the parent debt situation and also guidance on the stake sale of Hindustan Zinc is critical.

Kotak Institutional Equities is forecasting a 36% YoY decline in EBITDA due to weaker commodity prices across segments. However, sequential improvement in EBITDA to be led by moderation in costs.

Net sales are likely to decline 12% YoY to Rs 35,072 crore.

Cipla
In a seasonally weak quarter, Kotak is expecting Cipla to report a 5% YoY growth in domestic sales in the fourth quarter.

"We built in US sales of $198 million, up 1.5% QoQ, led by marginally higher Revlimid sales at $26 million and ramp-up of Leuprolide Acetate. We build in 16% yoy decline in South Africa (recovery expected from 1QFY24) and 19% yoy decline in ROW in 4QFY23," the brokerage said.

Net profit is expected to rise 31% to Rs 550 crore for the March quarter, while sales are seen growing 5% to Rs 5,527 crore

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)